You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華東醫藥(000963.SZ):博華製藥收購恒霸藥業100%股權 基礎價款5.28億元
格隆匯 07-21 17:11

格隆匯7月21日丨華東醫藥(000963.SZ)發佈公吿,2024年7月19日,公司、公司全資子公司華東醫藥(西安)博華製藥有限公司(以下簡稱“博華製藥”)與貴州恒霸藥業有限責任公司(以下簡稱“恒霸藥業”或“標的公司”)、何曉玲、何堯、貴州寶鼎辰璽科技有限公司(以下簡稱“貴州寶鼎”)、貴州鈐鈺企業管理服務有限責任公司(以下簡稱“貴州鈐鈺”)(以下合稱“交易對方”)簽訂《關於收購貴州恒霸藥業有限責任公司股權的協議書》,博華製藥收購恒霸藥業100%股權,交易基礎價款5.2847億元,並將根據協議約定支付浮動對價。

貴州恒霸藥業有限責任公司成立於1995年,是一家以研究開發苗族民族藥品為主,集中藥材種植、科研、生產、銷售為一體的國家高新技術企業。擁有中成藥文號21個、化藥文號2個;醫保甲類4個,醫保乙類10個,均為中成藥。目前在生產和銷售的主要產品為傷科靈噴霧劑、痺痛寧膠囊。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account